A U.S. Food and Drug Administration advisory committee has recommended authorization of Pfizer-BioNTech pediatric vaccine for ages 5 to 11.  

The next steps toward approval are the FDA authorization, discussion and recommendation by the Advisory Committee on Immunization Practices, scheduled to meet Nov. 2, and a final decision by the CDC director. The process could mean vaccination could begin in early November.